Clinical aspects of gastric cytoprotection.
D000284:Administration, Oral; D000535:Aluminum / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D001168:Arthritis / Q000188:drug therapy; D001241:Aspirin / Q000009:adverse effects; D002470:Cell Survival; D002986:Clinical Trials as Topic; D015232:Dinoprostone; D004311:Double-Blind Method; D004386:Duodenum / Q000166:cytology; D005744:Gastric Acid; D005753:Gastric Mucosa / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D011453:Prostaglandins / Q000502:physiology; D011458:Prostaglandins E / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000150:complications; D013392:Sucralfate
D000893:Anti-Inflammatory Agents; D011453:Prostaglandins; D011458:Prostaglandins E; D013392:Sucralfate; D011899:Ranitidine; D000535:Aluminum; D015232:Dinoprostone; D001241:Aspirin